JAZZ
Price
$106.90
Change
-$0.61 (-0.57%)
Updated
Jun 27 closing price
Capitalization
6.47B
31 days until earnings call
TECH
Price
$51.84
Change
-$0.96 (-1.82%)
Updated
Jun 27 closing price
Capitalization
8.13B
44 days until earnings call
Interact to see
Advertisement

JAZZ vs TECH

Header iconJAZZ vs TECH Comparison
Open Charts JAZZ vs TECHBanner chart's image
Jazz Pharmaceuticals
Price$106.90
Change-$0.61 (-0.57%)
Volume$871.45K
Capitalization6.47B
Bio-Techne
Price$51.84
Change-$0.96 (-1.82%)
Volume$2.49M
Capitalization8.13B
JAZZ vs TECH Comparison Chart in %
Loading...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAZZ vs. TECH commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a Buy and TECH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (JAZZ: $106.90 vs. TECH: $51.84)
Brand notoriety: JAZZ and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAZZ: 86% vs. TECH: 104%
Market capitalization -- JAZZ: $6.47B vs. TECH: $8.13B
JAZZ [@Biotechnology] is valued at $6.47B. TECH’s [@Biotechnology] market capitalization is $8.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAZZ’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 1 green FA rating(s).

  • JAZZ’s FA Score: 0 green, 5 red.
  • TECH’s FA Score: 1 green, 4 red.
According to our system of comparison, TECH is a better buy in the long-term than JAZZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAZZ’s TA Score shows that 3 TA indicator(s) are bullish while TECH’s TA Score has 6 bullish TA indicator(s).

  • JAZZ’s TA Score: 3 bullish, 6 bearish.
  • TECH’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, TECH is a better buy in the short-term than JAZZ.

Price Growth

JAZZ (@Biotechnology) experienced а -0.57% price change this week, while TECH (@Biotechnology) price change was +3.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

JAZZ is expected to report earnings on Jul 30, 2025.

TECH is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TECH($8.13B) has a higher market cap than JAZZ($6.47B). TECH has higher P/E ratio than JAZZ: TECH (62.46) vs JAZZ (14.53). JAZZ YTD gains are higher at: -13.195 vs. TECH (-27.826). JAZZ has higher annual earnings (EBITDA): 1.25B vs. TECH (283M). JAZZ has more cash in the bank: 2.57B vs. TECH (141M). TECH has less debt than JAZZ: TECH (423M) vs JAZZ (5.42B). JAZZ has higher revenues than TECH: JAZZ (4.07B) vs TECH (1.21B).
JAZZTECHJAZZ / TECH
Capitalization6.47B8.13B80%
EBITDA1.25B283M441%
Gain YTD-13.195-27.82647%
P/E Ratio14.5362.4623%
Revenue4.07B1.21B336%
Total Cash2.57B141M1,824%
Total Debt5.42B423M1,281%
FUNDAMENTALS RATINGS
JAZZ vs TECH: Fundamental Ratings
JAZZ
TECH
OUTLOOK RATING
1..100
6489
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
6080
PRICE GROWTH RATING
1..100
7662
P/E GROWTH RATING
1..100
9043
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for JAZZ (69) in the Pharmaceuticals Other industry. This means that TECH’s stock grew somewhat faster than JAZZ’s over the last 12 months.

TECH's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as JAZZ (100) in the Pharmaceuticals Other industry. This means that TECH’s stock grew similarly to JAZZ’s over the last 12 months.

JAZZ's SMR Rating (60) in the Pharmaceuticals Other industry is in the same range as TECH (80) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to TECH’s over the last 12 months.

TECH's Price Growth Rating (62) in the Biotechnology industry is in the same range as JAZZ (76) in the Pharmaceuticals Other industry. This means that TECH’s stock grew similarly to JAZZ’s over the last 12 months.

TECH's P/E Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for JAZZ (90) in the Pharmaceuticals Other industry. This means that TECH’s stock grew somewhat faster than JAZZ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAZZTECH
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
59%
Bearish Trend 3 days ago
70%
Momentum
ODDS (%)
Bearish Trend 3 days ago
62%
Bullish Trend 3 days ago
70%
MACD
ODDS (%)
Bearish Trend 3 days ago
49%
Bullish Trend 3 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
55%
Bullish Trend 3 days ago
68%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
61%
Bullish Trend 3 days ago
66%
Advances
ODDS (%)
Bullish Trend 20 days ago
61%
Bullish Trend 4 days ago
70%
Declines
ODDS (%)
Bearish Trend 17 days ago
55%
Bearish Trend 17 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
63%
Bearish Trend 3 days ago
70%
Aroon
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RTIYX11.890.08
+0.68%
Russell Inv Multifactor Intl Eq Y
LAMSX23.750.08
+0.34%
Lord Abbett Dividend Growth R4
RLBAX36.170.09
+0.25%
American Funds American Balanced R1
CFIGX14.050.01
+0.07%
Columbia Flexible Capital Income C
MCCRX16.390.01
+0.06%
MassMutual Small Cap Opps R3

JAZZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with TECH. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAZZ
1D Price
Change %
JAZZ100%
-0.57%
TECH - JAZZ
39%
Loosely correlated
-1.82%
FTRE - JAZZ
37%
Loosely correlated
-3.95%
BMRN - JAZZ
36%
Loosely correlated
+1.98%
ROIV - JAZZ
36%
Loosely correlated
-1.81%
EXEL - JAZZ
36%
Loosely correlated
+1.35%
More

TECH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TECH has been loosely correlated with ADPT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if TECH jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TECH
1D Price
Change %
TECH100%
-1.82%
ADPT - TECH
49%
Loosely correlated
-3.04%
SYRE - TECH
49%
Loosely correlated
-4.99%
TRDA - TECH
48%
Loosely correlated
-1.57%
DNLI - TECH
47%
Loosely correlated
-2.69%
XNCR - TECH
47%
Loosely correlated
-3.10%
More